Related Experiment Video
Updated: Apr 24, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
Are generic and brand-name statins clinically equivalent? Evidence from a real data-base.
Giovanni Corrao1, Davide Soranna2, Andrea Arfè1
1Department of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, Laboratory of Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy.
European Journal of Internal Medicine
|September 10, 2014
Summary
Generic statins are as effective as brand-name statins. This study found no significant differences in therapeutic interruption or cardiovascular outcomes between generic and brand-name statin users, supporting their comparable clinical utility.
Area of Science:
- Pharmacoeconomics
- Cardiovascular Medicine
- Drug Efficacy Studies
Background:
- Generic drug use is crucial for controlling healthcare costs.
- Concerns exist regarding potential clinical inferiority of generic versus brand-name medications.
- This study investigated the comparative effectiveness of generic and brand-name statins.
Purpose of the Study:
- To compare therapeutic interruption rates between patients using generic and brand-name statins.
- To assess differences in cardiovascular (CV) event rates for patients on generic versus brand-name statins.
- To evaluate the real-world clinical equivalence of generic and brand-name statins.
Main Methods:
- A cohort of 13,799 Italian patients aged 40+ initiating simvastatin (generic or brand-name) in 2008 was followed until 2011.
- Outcomes assessed included therapeutic discontinuation and CV event hospitalizations.
- Proportional hazard Cox models were used for intention-to-treat and as-treated analyses, with sensitivity analysis for confounders.
Main Results:
- Initiating generic statins showed no significant difference in discontinuation (HR: 0.98) or CV outcomes (HR: 0.98) compared to brand-name.
- Patients using generics for >75% of follow-up had similar discontinuation (HR: 0.94) and CV outcomes (HR: 1.06) versus predominantly brand-name users.
- Statistical analyses indicated no significant disparities in clinical effectiveness.
Conclusions:
- Real-world clinical practice does not support brand-name statins being superior to generics.
- Generic statins demonstrate comparable efficacy in maintaining therapy and preventing cardiovascular events.
- Findings suggest generic statins are a clinically equivalent alternative to brand-name statins.
More Related Videos
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
257
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
257
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
01:26Pharmaceutical Equivalents
270
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
270
01:16Bioequivalence Data: Statistical Interpretation
353
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
353
01:13Bioequivalence studies: Biowaivers
427
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
427